Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Accelerating Immune Response to Biodefense Vaccines

by Global Biodefense Staff
June 13, 2012

The deadline is fast approaching for companies to submit proposals towards advanced development of medical countermeasures for use in settings following the intentional release or naturally occurring outbreak of high priority pathogens.

The National Institute of Allergy and Infectious Diseases (NIAID) funding effort seeks to develop candidate products containing both a vaccine component and a technology that accelerates the immune response.

The Broad Agency Announcement (BAA) recognizes that use of vaccines in response to a significant bioterrorism or public health threat would be greatly enhanced by developing vaccines that are easy to deliver, produce protective immunity with one dose of vaccine and do not require a cold chain for storage or distribution.

Eligible vaccine candidate products include those for agents identified as NIAID Category A and B Priority Pathogens such as plague, smallpox, Q fever and tularemia, excluding B. anthracis. The technology components used in the proposed candidate product may, for example, consist of a new adjuvant, an immune modulator, a formulation technology or a delivery platform designed to enhance the protective immune response.

Per the BAA, simply changing a vaccine formulation, such as taking a liquid to a stable lyophilized vaccine formulation, would not be sufficient to meet the objectives.

The eventual goal is to enable the U.S. Government to stockpile these medical countermeasures and associated technologies to protect the American public following a biological event. Product developers should be cognizant of the logistical implications of using these products during a public health emergency.

NIAID estimates that one or more contracts may be issued for a total cost of up $44.5 million for a five-year period of performance. Full details are available under Solicitation Number: BAA-NIAID-DMID-NIHAI2010103. The final response deadline is June 23, 2012.

Tags: AnthraxBAABioterrorismPoxvirusesSmallpoxVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC